PRMT5 and adrenal cortex carcinoma: Taken together, our results pose PRMT5 as a putative target in ACC oncogenesis and provide a strong foundation for the clinical development of selective PRMT5 inhibitors as a targeted monotherapy or combination therapy for patients with ACC.